anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Computed tomography (CT) or "cat scan" is an x-ray test routinely used for diagnostic purposes. Heart ("Cardiac") CT, using the newest scanners, is an improved way of looking at the coronary arteries, which supply blood to the heart muscle. If these arteries are clogged this may cause chest pain or even a heart attack. The images of the coronary arteries obtained by CT scanners (during a 5-10 minute procedure) have been shown by many studies to be accurate, when compared to the conventional invasive cardiac catheterization procedure. In addition, at least five prior studies done at different hospitals suggest that cardiac CT scans are effective for diagnosing chest pain like yours in patients coming to the emergency room. What is new about this study is that it is being done in multiple hospitals at the same time. This is part of the process that all medical advances must go through to become a part of routine care of patients in hospitals throughout the country.

A standard chest pain workup typically done in the emergency department consists of a physical examination, electrocardiograms (EKGs), and several blood tests. Blood tests typically completed include cardiac enzymes (Troponin, CK \& CK-MB), a kidney function test, a pregnancy test if applicable, and possibly a lipid panel, depending on physician preference. For each test, a 3mL vial will be filled with a specimen of blood and processed in the laboratory for result. Also a two-part "rest-stress" nuclear scan is typically performed, which compares blood flow into the heart tissue at rest to blood flow into the heart tissue during exercise or dilation with medications. Based on prior studies, the researchers doing the present study believe that CT scanning of the coronary arteries can provide information that is just as safe and accurate as the rest-stress nuclear scan, and can do so more rapidly at a lower cost.
Life with food allergy training; The 2nd Intervention Group will share videos created by the trainer with the same training content and visuals as the face-to-face training group on the instagram page to be created on social media. At the same time, it is planned to share posts created from the training content on the actively used page. The participant parents will be ensured to follow the page actively, it will be confirmed that they see the posts by liking them and the follow-up will be done by the researcher.
Information regarding a patient's physiological signs is provided in real-time, in particular in conjunction with drug administration to the patient. A patient data input obtains patient data of a monitored patient. A drug identification input obtains drug administration data identifying a drug administered to the patient and the time of administration of the drug to the patient. A drug information input obtains drug information about the identified drug, including drug side effects and/or drug-drug interactions and/or drug-disease contraindications. A processing unit determines time-resolved monitoring information based on the obtained patient data, drug administration data and drug information. The monitoring information is dynamically adapted and one or more physiological signs of the patient that are most critical to monitor over time are indicated. An output interface outputs the monitoring information.
ETHNOPHARMACOLOGICAL RELEVANCE: Chi006Eese herbal medicine Weifuchun Tablets (WFC) approved by the State Food and Drug Administration in 1982 has been widely used in treating a variety of chronic stomach disorders including Chronic atrophic gastritis (CAG) and Gastric precancerous lesions in China clinically. This study aimed to investigate the efficacy and potential mechanism of WFC in treating Gastric intestinal metaplasia (GIM) and Gastric dysplasia (GDys).
MATERIALS AND METHODS: Rat GIM and GDys established by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) combined with hot paste, ethanol injury, and intermittent fasting were intervened by WFC. Body weight, histopathology, pH of gastric acid, pepsin activity, intestinal metaplasia index and inflammation were detected. Rat bone marrow derived macrophages (BMDMs) pretreated with WFC were stimulated by LPS. Inflammatory factors and the nuclear factor-kappa B (NF-κB) pathway were assessed. GES-1 cells pretreated by WFC were stimulated by MNNG and TNF-α, intestinal metaplasia index, the NF-κB pathway and interaction between P65 and CDX2 were detected.
RESULTS: WFC improved rat body weight, histopathology, pH value of gastric acid, activity of gastric pepsin, intestinal metaplasia (CDX2), inflammation (IL-1β, IL-6 and TNF-α), macrophage aggregation (CD68) in gastric mucosa in rat GIM and GDys. WFC inhibited inflammation (IL-1β and TNF-α) by inactivating the NF-κB pathway. WFC reduced the expression of CDX2 by inhibiting the binding of CDX2 promoter TSS upstream region with p65.
CONCLUSION: WFC blocked GIM and GDys associated with inflammation by regulating the NF-κB pathway.
PURPOSE:To obtain coated talc having excellent dispersibility, pigment characteristics, etc., by dispersing calcined talc in an aq. soln. of a water-soluble hydrolyzable metallic compd. to precipitate a metal oxide or hydroxide over the entire surface of the talc particle and achieve uniform coating. CONSTITUTION:An aq. soln. of a water-soluble hydrolyzable metallic compd. such as titanium sulfate, aluminum chloride, zinc sulfate, ferrous sulfate, cobalt chloride or sodium silicate is prepd. Calcined talc which has been calcined at 500-950 deg.C, is dispersed in this soln. to precipitate a metal hydroxide and/or a metal oxide over the entire surface of the talc particle. The coated talc is recovered by filtration and optionally calcined to obtain coated talc whose surface is completely coated with the metal hydroxide and/or the metal oxide and which is colored, in a desired color such as black, red, yellow, green or blue.
The present disclosure refers to a method and a system for generating a software-implemented module configured to determine concentration of an analyte in a sample of a bodily fluid. The method comprises providing, in one or more data processing devices, a first set of measurement data, the first set of measurement data representing first color information derived by image data processing from images for a region of interest of one or more test strips: generating a neural network model in a machine learning process applying an artificial neural network; and generating a software-implemented module comprising a first analyzing algorithm representing the neural network modei. The software-implemented module is configured to, when loaded into a data processing device having one or more processors, determine concentration of an analyte in a second sample of a bodily fluid from analyzing a second set of measurement data indicative of second color information derived by image processing from images for a region of interest of one or more test strips, the images being indicative of a color transformation of the region of interest in response to applying the second sample of the bodily fluid containing the analyte to the region of interest. Further, the present disclosure refers to a system for generating a software-implemented module as well as a method and a system for determining concentration of an analyte in a sample of a bodily fluid. Moreover, a computer program product is disclosed. (Fig. 1)
Neutropenia: Neutropenic deaths have been reported. Monitor for neutropenia with frequent blood cell counts. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features. Consider primary prophylaxis with G-CSF in all patients receiving a dose of 25 mg/m2 [see Contraindications (4) and Warnings and Precautions (5.1, 5.2)].

Severe hypersensitivity: Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy. Patients should receive premedication. JEVTANA is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80 [see Dosage and Administration (2.1), Contraindications (4), and Warnings and Precautions (5.3)].
OBJECTIVE: This study aimed to evaluate the effects of sterile saline solution irrigation (lavage) performed after mandibular third molar extraction on postoperative complications, utilizing a split-mouth randomized clinical trial design.
METHODS: Seventeen healthy participants requiring bilateral mandibular third molar extraction were enrolled in this single-center study. In each participant, one impacted third molar was designated as the experimental group and subjected to saline lavage at 4 °C. In contrast, the control group was the other impacted third molar, undergoing saline lavage at 25 °C. Various parameters, including postoperative pain, mouth opening, and facial swelling, were assessed using standardized measures and three-dimensional facial scanning at multiple time points.
RESULTS: The average age of participants was 26.66 ± 4.1 years, with no postoperative complications observed in either group. The duration of surgery did not significantly differ between groups. Postoperative pain was significantly reduced in the experimental group during the immediate postoperative period compared with the control group, but this difference diminished over time. No significant differences were observed in mouth opening or facial swelling between groups at any time.
CONCLUSION: In site 4 °C, sterile saline solution irrigation after mandibular third molar extraction may effectively reduce early postoperative complications, particularly pain, without prolonging surgical duration.
STUDY'S GOAL: Our goal is to enrich the medical literature by sharing our experience in managing a case of sub-acute upper limb ischemia that revealed Horton's disease. This is particularly relevant given the current lack of well-established guidelines.
INTRODUCTION: Acute upper limb ischemia is rarely seen in Horton's disease.
CASE REPORT: We present a case of a 63-year-old female patient with sub-acute ischemia in both upper limbs, accompanied by jaw claudication and absence of bilateral temporal pulses. The CT Angiography scan revealed bilateral occlusions and stenosis of the axillary and sub-clavier arteries, as well as involvement of the external carotid arteries and its branches. The Arteriography confirmed abnormalities in the medium-sized arteries of the supra-aortic trunks. The histopathology examination of the temporal artery biopsy was negative. The patient received emergency corticosteroid therapy followed by an immunosuppressant. Due to the improved clinical condition of the upper limbs, surgical intervention was not performed.
Individually titrate oral transmucosal fentanyl citrate to a dose that provides adequate analgesia and minimizes side effects. The initial dose of oral transmucosal fentanyl citrate to treat episodes of breakthrough cancer pain is always 200 mcg. The oral transmucosal fentanyl citrate unit should be consumed over 15 minutes. Patients should be prescribed an initial titration supply of six 200 mcg oral transmucosal fentanyl citrate units, thus limiting the number of units in the home during titration. Patients should use up all units before increasing to a higher dose to prevent confusion and possible overdose.

Repeat Dosing   
a. In cases where the breakthrough pain episode is not relieved after 15 minutes after completion of the oral transmucosal fentanyl citrate unit (30 minutes after the start of the unit), patients may take ONLY ONE additional dose using the same strength for that episode. Thus patients should take a maximum of two doses of oral transmucosal fentanyl citrate for any episode of breakthrough pain.

b. Patients MUST wait at least 4 hours before treating another episode of breakthrough pain with oral transmucosal fentanyl citrate.
BACKGROUND: Rare cystic lung diseases are increasingly recognised due the wider application of CT scanning making cystic lung disease management a growing part of respiratory care. Cystic lung diseases tend to have extrapulmonary features that can both be diagnostic but also require surveillance and treatment in their own right. As some of these diseases now have specific treatments, making a precise diagnosis is crucial. While Langerhans cell histiocytosis, Birt-Hogg-Dubé syndrome, lymphoid interstitial pneumonia and lymphangioleiomyomatosis are becoming relatively well-known diseases to respiratory physicians, a targeted and thorough workup improves diagnostic accuracy and may suggest other ultrarare diseases such as light chain deposition disease, cystic pulmonary amyloidosis, low-grade metastatic neoplasms or infections. In many cases, diagnostic information is overlooked leaving uncertainty over the disease course and treatments.
AIMS: This position statement from the Rare Disease Collaborative Network for cystic lung diseases will review how clinical, radiological and physiological features can be used to differentiate between these diseases.
NARRATIVE: We highlight that in many cases a multidisciplinary diagnosis can be made without the need for lung biopsy and discuss where tissue sampling is necessary when non-invasive methods leave diagnostic doubt. We suggest an initial workup focusing on points in the history which identify key disease features, underlying systemic and familial diseases and a clinical examination to search for connective tissue disease and features of genetic causes of lung cysts. All patients should have a CT of the thorax and abdomen to characterise the pattern and burden of lung cysts and extrapulmonary features and also spirometry, gas transfer and a 6 min walk test. Discussion with a rare cystic lung disease centre is suggested before a surgical biopsy is undertaken.
CONCLUSIONS: We suggest that this focused workup should be performed in all people with multiple lung cysts and would streamline referral pathways, help guide early treatment, management decisions, improve patient experience and reduce overall care costs. It could also potentially catalyse a national research database to describe these less well-understood and unidentified diseases, categorise disease phenotypes and outcomes, potentially leading to better prognostic data and generating a stronger platform to understand specific disease biology.
Studies have demonstrated that the external bacterial flora of the patients in most cases is the actual source of infection. The objective of antisepsis is to eliminate or significantly reduce the number of microorganisms in the surgical field at the time of surgery. The eyelids and the conjunctiva are considered to be quite common sources of bacteria that can lead to endophthalmitis. Thus, it is believed that by reducing the number and growth of bacteria on the ocular surface and adnexa before surgery, the risk of postoperative infection would be lower. Povidone-iodine 5% eye drops has been used in preoperative cataract surgery to prevent endophthalmitis and is the standard prophylactic action in preventing postoperative endophthalmitis being widely compared with other antibiotic eye drops and their associations. The standard procedure of prophylaxis of postoperative endophthalmitis corresponds to applying a single drop of povidone-iodine 2min before any intraocular surgical procedure. However, few studies have assessed the effectiveness of povidone-iodine 5% eye drops using different dosing regimens to achieve the best bactericidal effect. The aim of this study is to investigate different dosages with respect to the use of povidone-iodine drops to optimize the effectiveness of the agent, ensuring the best exogenous endophthalmitis prophylaxis.
PURPOSE:To obtain a preventive and remedy for hypertension having immediate effects free from side effects, containing a calcium hexose phosphate as an active ingredient. CONSTITUTION:A calcium hexose phosphate (e.g. calcium glucose-1-phosphate) and, if necessary, a given carrier for preparation, excipient, etc., are pharmaceutically manufactured by a conventional procedure to give the aimed substance. The substance can be made into tablets, granules, capsule agents, oral administration agent, etc. A dose is 0.1-20g, preferably 1-15g calculated as calcium hexose per person daily. Acute toxicity of mouse of calcium glucose-1-phosphate is >=15,000mg/kg and the substance is extremely safe. The substance can suppress rise in blood pressure and prevent and treat diseases such as myocardial infarction, cerebral apoplexy, liver cirrhosis, cholestasia, etc., wherein hypertension is considered one cause of crisis.
A chorionic peptidase-1 (C-ase-1) which is isolated from human placenta that inactivates the immunoreactivity of GnRH, TRH and angiotension II. Only in the presence of dithiothreitol (DDT), a sulfhydryl agent, are oxytocin and somatostatin inactivated by this peptidase. However, C-ase-1 is without effect on CRF, hCS or hCG. C-ase-1 also inhibits the biological activity of GnRH, i.e. its ability to stimulate pituitary LH and FSH. The ability of this peptidase to inactivate GnRH, TRH and angiotension II can be inhibited by various peptidase inhibitors. These peptidase inhibitors include bacitracin, para-amino bensamidine, DMSO and diisopropylfluorophosphate. The activity of C-ase-1 in GnRH has also been demonstrated to be a post-proline peptidase. Isolation of this protein, C-ase-1, has been effected using permeation, ion exchange and affinity chromatography and HPLC. As estimated by SDS-PAGE and HPLC analysis, C-ase-1 has an apparent molecular weight of about 58,000 daltons. It is proposed that C-ase-1 may be an important chorionic regulator of GnRH, TRH and angiotension II levels during pregnancy.
Compositions of dendrimers conjugated with one or more therapeutic agents that decrease exosome secretion and methods of use thereof for treating, alleviating, and/or preventing one or more symptoms associated with one or more neurological disease or disorders, cancer, inflammatory diseases, bacterial and viral infections, and other disorders have been developed. Preferably, the therapeutic agents are one or more agents that inhibit or reduce activity and/or quantity of neutral sphingomyelinase 2 (nSMase2) such as small molecule inhibitors of nSMase2. Compositions are particularly suited for reducing A? plaque formation, reducing tau propagation, improving cognition, or combinations thereof in a subject with psychiatric and neurological disorders. Compositions are also suited for treating, alleviating, and/or preventing one or more symptoms associated with cancer, bacterial and viral infections, and inflammatory diseases. Methods of treating a human subject having one or more of the diseases and disorders are provided.
Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug‑controlled studies that enrolled patients with the following seizure types:

  1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types.
  2. Generalized tonic-clonic seizures (grand mal).
  3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General).
P450 Interaction: In vitro metabolism studies showed that CYP1A2 was the major enzyme responsible for the metabolism of ropinirole. There is thus the potential for substrates or inhibitors of this enzyme when coadministered with ropinirole to alter its clearance. Therefore, if therapy with a drug known to be a potent inhibitor of CYP1A2 is stopped or started during treatment with ropinirole hydrochloride, adjustment of the dose of ropinirole hydrochloride may be required.

L-dopa: Co-administration of carbidopa + L-dopa (SINEMET® 10/100 mg twice daily) with ropinirole (2 mg 3 times daily) had no effect on the steady-state pharmacokinetics of ropinirole (n = 28 patients). Oral administration of ropinirole hydrochloride 2 mg 3 times daily increased mean steady state Cmax of L-dopa by 20%, but its AUC was unaffected (n = 23 patients).

Digoxin: Co-administration of ropinirole hydrochloride (2 mg 3 times daily) with digoxin (0.125 to 0.25 mg once daily) did not alter the steady-state pharmacokinetics of digoxin in 10 patients.

Theophylline: Administration of theophylline (300 mg twice daily, a substrate of CYP1A2) did not alter the steady-state pharmacokinetics of ropinirole (2 mg 3 times daily) in 12 patients with Parkinson's disease. Ropinirole (2 mg 3 times daily) did not alter the pharmacokinetics of theophylline (5 mg/kg IV) in 12 patients with Parkinson's disease.

Ciprofloxacin: Co-administration of ciprofloxacin (500 mg twice daily), an inhibitor of CYP1A2, with ropinirole (2 mg 3 times daily) increased ropinirole AUC by 84% on average and Cmax by 60% (n = 12 patients).

Estrogens: Population pharmacokinetic analysis revealed that estrogens (mainly ethinylestradiol: intake 0.6 to 3 mg over 4-month to 23-year period) reduced the oral clearance of ropinirole by 36% in 16 patients. Dosage adjustment may not be needed for ropinirole hydrochloride in patients on estrogen therapy because patients must be carefully titrated with ropinirole to tolerance or adequate effect. However, if estrogen therapy is stopped or started during treatment with ropinirole hydrochloride, then adjustment of the dose of ropinirole hydrochloride may be required.

Dopamine Antagonists: Since ropinirole is a dopamine agonist, it is possible that dopamine antagonists such as neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide may diminish the effectiveness of ropinirole hydrochloride. Patients with major psychotic disorders treated with neuroleptics should only be treated with dopamine agonists if the potential benefits outweigh the risks. 

Population analysis showed that commonly administered drugs, e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, and anticholinergics, did not affect the oral clearance of ropinirole.